OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

ASTRAZENECA PLC-SPONS ADR/  US0463531089  /

Vienna Global Market
2024-11-08  3:30:33 PM Chg. +1.50 Volume Bid5:29:26 PM Ask5:29:26 PM Market Capitalization Dividend Y. P/E Ratio
60.50EUR +2.54% 0
Turnover: -		 -Bid Size: - -Ask Size: - 186.02 bill.EUR - -

Business description

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 

Management board & Supervisory board

CEO
Pascal Soriot
Management board
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr
Supervisory board
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz
 

Company data

Name: AstraZeneca plc
Address: 1 Francis Crick Avenue Cambridge Biomedical Campus,Cambridge, CB2 0AA United Kingdom
Phone: 0800 783 0033
Fax: +44-20-7604-8151
E-mail: Medical.InformationU...eca.com Medical.InformationUK@astrazeneca.com
Internet: www.astrazeneca.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: -
IPO date: 1999-04-06

Investor relations

Name: Andy Barnett
IR phone: +44 (0)20 3749 5000
IR Fax: -
IR e-mail: CorporateAccess@astrazeneca

Company calendar

CW 46 | 2024-11-12 Interim Report 3rd Quarter/9 Months
 

Main Shareholders